Published in Cancer Res on March 01, 2011
A systematic review of microRNA in glioblastoma multiforme: micro-modulators in the mesenchymal mode of migration and invasion. Mol Neurobiol (2012) 1.44
Current Understanding on EGFR and Wnt/β-Catenin Signaling in Glioma and Their Possible Crosstalk. Genes Cancer (2013) 1.28
FoxM1 and Wnt/β-catenin signaling in glioma stem cells. Cancer Res (2012) 1.26
Acute and fractionated irradiation differentially modulate glioma stem cell division kinetics. Cancer Res (2012) 1.25
Brain tumor stem cells: Molecular characteristics and their impact on therapy. Mol Aspects Med (2013) 1.14
Wnt/β-catenin signaling is a key downstream mediator of MET signaling in glioblastoma stem cells. Neuro Oncol (2012) 1.09
MiR-328 promotes glioma cell invasion via SFRP1-dependent Wnt-signaling activation. Neuro Oncol (2013) 1.04
GPCRs and cancer. Acta Pharmacol Sin (2012) 1.02
The evolving landscape of glioblastoma stem cells. Curr Opin Neurol (2013) 1.02
Targeting the Wnt pathway in human cancers: therapeutic targeting with a focus on OMP-54F28. Pharmacol Ther (2014) 1.00
Cancer stem cell contribution to glioblastoma invasiveness. Stem Cell Res Ther (2013) 0.98
Stem cell niches in glioblastoma: a neuropathological view. Biomed Res Int (2014) 0.96
CXCL12 modulation of CXCR4 and CXCR7 activity in human glioblastoma stem-like cells and regulation of the tumor microenvironment. Front Cell Neurosci (2014) 0.96
Reciprocal activation of transcription factors underlies the dichotomy between proliferation and invasion of glioma cells. PLoS One (2013) 0.93
Targeting gallbladder cancer: oncolytic virotherapy with myxoma virus is enhanced by rapamycin in vitro and further improved by hyaluronan in vivo. Mol Cancer (2014) 0.92
Frizzled homolog proteins, microRNAs and Wnt signaling in cancer. Int J Cancer (2012) 0.89
Proliferation and enrichment of CD133(+) glioblastoma cancer stem cells on 3D chitosan-alginate scaffolds. Biomaterials (2014) 0.89
A unique combination of male germ cell miRNAs coordinates gonocyte differentiation. PLoS One (2012) 0.87
Glioblastoma stem cells: Molecular characteristics and therapeutic implications. World J Stem Cells (2014) 0.86
Tumor-initiating cells and FZD8 play a major role in drug resistance in triple-negative breast cancer. Mol Cancer Ther (2013) 0.85
Assessing current therapeutic approaches to decode potential resistance mechanisms in glioblastomas. Front Oncol (2013) 0.85
WNT signaling in glioblastoma and therapeutic opportunities. Lab Invest (2015) 0.84
Heterogeneous nuclear ribonucleoprotein C1/C2 controls the metastatic potential of glioblastoma by regulating PDCD4. Mol Cell Biol (2012) 0.84
Epithelial-mesenchymal transition in glioblastoma progression. Oncol Lett (2016) 0.84
Profiling gene promoter occupancy of Sox2 in two phenotypically distinct breast cancer cell subsets using chromatin immunoprecipitation and genome-wide promoter microarrays. Breast Cancer Res (2014) 0.83
TLR9 is critical for glioma stem cell maintenance and targeting. Cancer Res (2014) 0.83
Long noncoding RNA AK126698 inhibits proliferation and migration of non-small cell lung cancer cells by targeting Frizzled-8 and suppressing Wnt/β-catenin signaling pathway. Onco Targets Ther (2016) 0.83
Changes in the biological characteristics of glioma cancer stem cells after serial in vivo subtransplantation. Childs Nerv Syst (2012) 0.82
Epidermal to Mesenchymal Transition and Failure of EGFR-Targeted Therapy in Glioblastoma. Cancers (Basel) (2012) 0.82
Crosstalk of the Wnt/β-catenin pathway with other pathways in cancer cells. Genes Dis (2016) 0.81
Dedifferentiation of patient-derived glioblastoma multiforme cell lines results in a cancer stem cell-like state with mitogen-independent growth. J Cell Mol Med (2015) 0.81
Spatio-temporal expression pattern of frizzled receptors after contusive spinal cord injury in adult rats. PLoS One (2012) 0.81
Identification and characterization of a small-molecule inhibitor of Wnt signaling in glioblastoma cells. Mol Cancer Ther (2013) 0.81
In vivo RNAi screen identifies NLK as a negative regulator of mesenchymal activity in glioblastoma. Oncotarget (2015) 0.80
Pharmacologic Wnt Inhibition Reduces Proliferation, Survival, and Clonogenicity of Glioblastoma Cells. J Neuropathol Exp Neurol (2015) 0.78
Overexpression of Pygopus-2 is required for canonical Wnt activation in human lung cancer. Oncol Lett (2013) 0.77
Pharmacological folding chaperones act as allosteric ligands of Frizzled4. Nat Chem Biol (2015) 0.77
RYK promotes the stemness of glioblastoma cells via the WNT/ β-catenin pathway. Oncotarget (2017) 0.75
Enhanced targeting of CML stem and progenitor cells by inhibition of porcupine acyltransferase in combination with TKI. Blood (2016) 0.75
Glioblastoma multiforme formation and EMT: role of FoxM1 transcription factor. Curr Pharm Des (2015) 0.75
EMT and MET-related processes in non-epithelial tumors: importance for disease progression, prognosis and therapeutic opportunities. Mol Oncol (2017) 0.75
Cancer stem cell-related gene expression as a potential biomarker of response for first-in-class imipridone ONC201 in solid tumors. PLoS One (2017) 0.75
A highly annotated whole-genome sequence of a Korean individual. Nature (2009) 6.91
SSEA-1 is an enrichment marker for tumor-initiating cells in human glioblastoma. Cell Stem Cell (2009) 3.89
Recent advances in 2D and 3D in vitro systems using primary hepatocytes, alternative hepatocyte sources and non-parenchymal liver cells and their use in investigating mechanisms of hepatotoxicity, cell signaling and ADME. Arch Toxicol (2013) 3.00
Clinical and biological implications of CD133-positive and CD133-negative cells in glioblastomas. Lab Invest (2008) 2.79
Phosphorylation of EZH2 activates STAT3 signaling via STAT3 methylation and promotes tumorigenicity of glioblastoma stem-like cells. Cancer Cell (2013) 2.38
Development of a T1 contrast agent for magnetic resonance imaging using MnO nanoparticles. Angew Chem Int Ed Engl (2007) 2.19
CD44-negative cells in head and neck squamous carcinoma also have stem-cell like traits. Eur J Cancer (2012) 2.08
Leptomeningeal carcinomatosis in non-small-cell lung cancer patients: impact on survival and correlated prognostic factors. J Thorac Oncol (2013) 1.93
A single recurrent mutation in the 5'-UTR of IFITM5 causes osteogenesis imperfecta type V. Am J Hum Genet (2012) 1.70
The polymerase acidic protein gene of influenza a virus contributes to pathogenicity in a mouse model. J Virol (2009) 1.68
Prognostic significance of c-Met expression in glioblastomas. Cancer (2009) 1.68
A genome-wide association study identifies a breast cancer risk variant in ERBB4 at 2q34: results from the Seoul Breast Cancer Study. Breast Cancer Res (2012) 1.62
Atypical spontaneous intracranial hypotension (SIH) with nonorthostatic headache. Headache (2007) 1.58
Relationship between malignant subtypes of meningioma and clinical outcome. J Clin Neurosci (2007) 1.58
Double antiangiogenic protein, DAAP, targeting VEGF-A and angiopoietins in tumor angiogenesis, metastasis, and vascular leakage. Cancer Cell (2010) 1.47
Patient-specific orthotopic glioblastoma xenograft models recapitulate the histopathology and biology of human glioblastomas in situ. Cell Rep (2013) 1.44
Bcl2L12 inhibits post-mitochondrial apoptosis signaling in glioblastoma. Genes Dev (2007) 1.38
ID4 imparts chemoresistance and cancer stemness to glioma cells by derepressing miR-9*-mediated suppression of SOX2. Cancer Res (2011) 1.37
Inhibitor of differentiation 4 drives brain tumor-initiating cell genesis through cyclin E and notch signaling. Genes Dev (2008) 1.34
miR-506 regulates epithelial mesenchymal transition in breast cancer cell lines. PLoS One (2013) 1.31
MET signaling regulates glioblastoma stem cells. Cancer Res (2012) 1.29
Neuronal Elav-like (Hu) proteins regulate RNA splicing and abundance to control glutamate levels and neuronal excitability. Neuron (2012) 1.27
EGFR-AKT-Smad signaling promotes formation of glioma stem-like cells and tumor angiogenesis by ID3-driven cytokine induction. Cancer Res (2011) 1.25
CXCR4 signaling regulates metastasis of chemoresistant melanoma cells by a lymphatic metastatic niche. Cancer Res (2010) 1.24
Diagnostic application of targeted resequencing for familial nonsyndromic hearing loss. PLoS One (2013) 1.24
Wnt activation is implicated in glioblastoma radioresistance. Lab Invest (2011) 1.22
Cancer stem cell traits in squamospheres derived from primary head and neck squamous cell carcinomas. Oral Oncol (2010) 1.22
Inhibitory effect of (-)-epigallocatechin-3-gallate on lipid accumulation of 3T3-L1 cells. Obesity (Silver Spring) (2007) 1.19
Thymic OX40 expression discriminates cells undergoing strong responses to selection ligands. J Immunol (2009) 1.18
IL-6 protects pancreatic islet beta cells from pro-inflammatory cytokines-induced cell death and functional impairment in vitro and in vivo. Transpl Immunol (2004) 1.16
Metronomic treatment of temozolomide inhibits tumor cell growth through reduction of angiogenesis and augmentation of apoptosis in orthotopic models of gliomas. Oncol Rep (2006) 1.15
A pilot study of metronomic temozolomide treatment in patients with recurrent temozolomide-refractory glioblastoma. Oncol Rep (2006) 1.15
Chitosan-graft-polyethylenimine as a gene carrier. J Control Release (2006) 1.15
CCDC41 is required for ciliary vesicle docking to the mother centriole. Proc Natl Acad Sci U S A (2013) 1.13
Virulence and genetic compatibility of polymerase reassortant viruses derived from the pandemic (H1N1) 2009 influenza virus and circulating influenza A viruses. J Virol (2011) 1.13
Ecology of H3 avian influenza viruses in Korea and assessment of their pathogenic potentials. J Gen Virol (2008) 1.13
Targeted disruption of hsp70.1 sensitizes to osmotic stress. EMBO Rep (2002) 1.13
Whole-exome sequencing identifies mutations of KIF22 in spondyloepimetaphyseal dysplasia with joint laxity, leptodactylic type. Am J Hum Genet (2011) 1.13
Phase II trial of low-dose continuous (metronomic) treatment of temozolomide for recurrent glioblastoma. Neuro Oncol (2010) 1.11
Efficacy of stereotactic radiosurgery as a salvage treatment for recurrent malignant gliomas. Cancer (2008) 1.11
LIN28B confers radio-resistance through the posttranscriptional control of KRAS. Exp Mol Med (2009) 1.11
Splicing variant of AIMP2 as an effective target against chemoresistant ovarian cancer. J Mol Cell Biol (2012) 1.10
Clinical outcome of concomitant chemoradiotherapy followed by adjuvant temozolomide therapy for glioblastaomas: single-center experience. Clin Neurol Neurosurg (2009) 1.10
Up-regulation of PDCD4 in senescent human diploid fibroblasts. Biochem Biophys Res Commun (2002) 1.09
Wnt/β-catenin signaling is a key downstream mediator of MET signaling in glioblastoma stem cells. Neuro Oncol (2012) 1.09
Cancer-Specific requirement for BUB1B/BUBR1 in human brain tumor isolates and genetically transformed cells. Cancer Discov (2012) 1.07
Proposed mechanisms of (-)-epigallocatechin-3-gallate for anti-obesity. Chem Biol Interact (2007) 1.07
Genomic profiling combined with gene expression profiling in primary central nervous system lymphoma. Blood (2010) 1.06
Inhibition of platelet-derived growth factor receptor signaling restricts the growth of human breast cancer in the bone of nude mice. Clin Cancer Res (2005) 1.05
FOXO3a turns the tumor necrosis factor receptor signaling towards apoptosis through reciprocal regulation of c-Jun N-terminal kinase and NF-kappaB. Arterioscler Thromb Vasc Biol (2007) 1.03
Exploration of molecular genetic etiology for Korean cochlear implantees with severe to profound hearing loss and its implication. Orphanet J Rare Dis (2014) 1.03
Cationic oligopeptide-mediated delivery of dsRNA for post-transcriptional gene silencing in plant cells. FEBS Lett (2004) 1.03
An atypical E3 ligase zinc finger protein 91 stabilizes and activates NF-kappaB-inducing kinase via Lys63-linked ubiquitination. J Biol Chem (2010) 1.03
A statin-regulated microRNA represses human c-Myc expression and function. EMBO Mol Med (2012) 1.03
Antibacterial and biofilm removal activity of a podoviridae Staphylococcus aureus bacteriophage SAP-2 and a derived recombinant cell-wall-degrading enzyme. Appl Microbiol Biotechnol (2009) 1.02
Genome-wide promoter methylation analysis identifies epigenetic silencing of MAPK13 in primary cutaneous melanoma. Pigment Cell Melanoma Res (2013) 1.02
Activation of notch signaling in a xenograft model of brain metastasis. Clin Cancer Res (2008) 1.02
Combination celecoxib and temozolomide in C6 rat glioma orthotopic model. Oncol Rep (2006) 1.00
Identification and characterization of new microRNAs from pig. Mamm Genome (2008) 1.00
Enhanced liver functions of hepatocytes cocultured with NIH 3T3 in the alginate/galactosylated chitosan scaffold. Biomaterials (2005) 0.99
Genetically engineered human neural stem cells with rabbit carboxyl esterase can target brain metastasis from breast cancer. Cancer Lett (2011) 0.99
Functional catechol-O-methyltransferase gene polymorphism and susceptibility to schizophrenia. Eur Neuropsychopharmacol (2002) 0.99
Dcr3 inhibit p53-dependent apoptosis in gamma-irradiated lung cancer cells. Int J Radiat Biol (2010) 0.98
Adenovirus-TRAIL can overcome TRAIL resistance and induce a bystander effect. Cancer Gene Ther (2003) 0.98
Comprehensive analysis of time- and dose-dependent patterns of gene expression in a human mesenchymal stem cell line exposed to low-dose ionizing radiation. Oncol Rep (2008) 0.97
Pharmacokinetic study of ginsenoside Re with pure ginsenoside Re and ginseng berry extracts in mouse using ultra performance liquid chromatography/mass spectrometric method. J Pharm Biomed Anal (2009) 0.97
The neural stem cell fate determinant TLX promotes tumorigenesis and genesis of cells resembling glioma stem cells. Mol Cells (2010) 0.97
Forkhead factor, FOXO3a, induces apoptosis of endothelial cells through activation of matrix metalloproteinases. Arterioscler Thromb Vasc Biol (2007) 0.96
Design and application of chitosan microspheres as oral and nasal vaccine carriers: an updated review. Int J Nanomedicine (2012) 0.96
Gene expression profiling of anti-GBM glomerulonephritis model: the role of NF-kappaB in immune complex kidney disease. Kidney Int (2004) 0.96
Prevalence of p.V37I variant of GJB2 in mild or moderate hearing loss in a pediatric population and the interpretation of its pathogenicity. PLoS One (2013) 0.96